摘要
本课题参照部颁标准中生脉注射液的处方及诸多相关文献,将西洋参、五味子、麦冬配伍,对三味中药分别进行提取及纯化精制,制备成注射级中间体干燥品;分别对其进行质量研究并建立相应专属性质量标准;以制得的中间体为原料,筛选出合适的处方和冷冻干燥工艺,制备注射用洋参生脉粉针;制定准确、严密的质量标准并建立麦冬、五味子药材及其中间体和制剂的指纹图谱,从而有效控制产品质量;考察注射用洋参生脉的一般安全性,以保证临床用药的安全;对本品在改善心肌缺血及心律失常方面进行初步药效研究,为临床给药奠定基础。
首先,针对注射剂要求及工业化生产规模,采用单因素考察及正交设计试验,以各自有效成分的转移率为指标,对处方中三味中药分别进行乙醇提取及大孔树脂纯化工艺的筛选与优化,确定了各注射级中间体的制备工艺。
以西洋参二醇组皂苷(Rd、Rc、Rb_3、Rb_2、Rb_1、Rg_3)及pF_(11)的转移率为指标,制备注射用西洋参二醇组皂苷,制备过程中其总转移率为64.9%;以甾体总皂苷(以麦冬皂苷D′计)、总黄酮(以橙皮苷计)的转移率为指标,制备注射用麦冬标准化提取物,制备过程中其总转移率分别为64.3%、66.4%;以总木脂素(五味子醇甲、五味子甲素及五味子乙素三种有效成分之和)的转移率为指标,制备注射用五味子标准化提取物,制备过程中其总转移率为65.7%。
对三个注射级中间体干燥品进行质量研究并建立相应专属性质量标准。检测结果显示三者均符合注射级质量要求,可直接作为二次配料制备注射剂。
运用HPLC-ELSD法对注射用西洋参二醇组皂苷中的各单体皂苷同时进行含量测定,规定西洋参二醇组皂苷(Rd、Rc、Rb_3、Rb_2、Rb_1、Rg_3)及pF_(11)的含量总计不低于70%;并测定了总皂苷含量,规定其总皂苷含量不低于95.0%。测定了注射用麦冬标准化提取物中总皂苷及总黄酮含量,规定二者含量分别不低于60.0%、5.0%。采用HPLC法,对注射用五味子标准化提取物中的五味子醇甲、五味子甲素、五味子乙素进行含量测定,规定三者含量总计不低于95.0%;同时测定了总木脂素含量,规定其总木脂素含量不低于58.0%。
以外观、含水量和复溶性为指标,优化冻干制剂处方,确立了甘露醇100mg/瓶作为支撑剂的处方及冻干工艺。配伍试验研究表明本品和生理盐水注射液,5.0%葡萄糖注射液配伍相容性良好(12h)。
对注射用洋参生脉粉针进行质量研究,结果表明产品符合中药注射用无菌制品的质量要求,并建立专属性质量标准,以有效控制产品质量,保证临床用药的安全。
分别运用HPLC-ELSD法测定各西洋参单体皂苷的含量、HPLC法测定五味子醇甲的含量、紫外-分光分光光度法测定总皂苷、总木脂素的含量:规定本品每瓶含西洋参二醇组皂苷(Rd、Rc、Rb_3、Rb_2、Rb_1、Rg_3)及pF_(11)总计不低于21.0mg;五味子醇甲不低于0.38mg;总皂苷(以人参皂苷Rd计)不低于67mg;含总木脂素(以五味子醇甲计)不低于1.50mg。
建立了麦冬、五味子药材及其中间体和制剂的指纹图谱。结果表明,药材及其中间体和制剂中指纹图谱方法学考察符合要求,10批药材及其中间体和制剂间相对保留时间、非共有峰峰面积、共有指纹峰峰面积比值等各项指标均在规定范围以内,药材及其中间体和制剂间指纹图谱相关性良好。
对注射用洋参生脉粉针的体外溶血、过敏性和血管刺激性进行了考察,结果表明本品的安全性达到注射剂的要求。小鼠急性毒性试验的LD_(50)及95%可信限为492.9mg/kg和438.2~554.5mg/kg(以总皂苷与总木脂素总量计)。
药效学试验结果表明,本品大鼠腹腔给药16.8mg/kg以上,对Iso所致大鼠心电图变化有明显的抑制作用;静脉给药24mg/kg以上,对夹闭小鼠气管其心电消失时间有显著的延长作用、对氯仿诱发小鼠室颤的发生率有明显的抑制作用;静脉给药16.8mg/kg以上对氯化钡引起的心律不齐维持时间有显著缩短作用。提示注射用洋参生脉粉针可用于缺血性心脏病及心律失常的治疗。
This thesis aimed to investigate the extractions of Panax quinquefolium L., Ophiopogon japonicus and Schisandra Chinensis and the combination of three extracts. The freezing-dry intermediates for injection of three extracts were manufactured and quality specification were established. To prepare Yangsheng Shengmai Freezing-dry Preparation (YSFP) for injection from the intermediates and maintain the qualities of the product, the formula and the and drying processes were optimized; an accurate and sensitive quality specification of freezing-dry products and the fingerprint chromatograms of Ophiopogon japonicus, Schisandra Chinensis, the intermediates and the preparation were established. The investigation of common safety and pharmacodynamics experiments provided experimental data for clinical application of YSFP.The extracting with alcohol and purifying with macroporous resin processes of three kinds of Chinese traditional medicine were optimized by using factor experiment and orthogonal design, As the response, the transfer proportion of each active ingredient was evaluated. The formulation and preparation process of each intermediates for injection were determined according to result of experiments.The purification process of the active constituents of Panax quinquefolium L. is studied by the criterion of transference rate of Rd, Rc, Rb_3, Rb_2, Rb_1, Rg_3, pF_(11). The result indicated that the total transference rate was 64.9%. The purification process of the active constituents of Ophiopogon japonicus is studied by the criterion of transference rate of total saponins and total flavonoids. The result indicated that the total transference rate was 64.3%, 66.4%. The purification process of the active constituents of Schisandra Chinensis is studied by the criterion of transference rate of total lignans. The result indicated that the total transference rate was 65.7%.Qualities of the three intermediates for injection were studied separately and built up corresponded. The results showed that all of them were agree with the quality requirements of preparation for injection.HPLC-ELSD method was used to determine the sing saponin from PQDS, which regulated all of the contents of Rd, Rc, Rb_3, Rb_2, Rb_1, Rg_3, pF_(11) should be more than 70.0%, at the same time. The contents determination on total saponins were determined and regulated more than 60.0%. The contents determination for Ophiopogon japonicus intermediate on total saponins and total flavonoids were determined and regulated more than 60.0% and 5.0%. HPLC and UV methods were set up to determine contents of lignans in the Schisandra Chinensis intermediate and regulated more than 15.0%, 58.0%.The prescription of freezing-dry preparation was optimized by the criterion of appearance, water content and re-solubility. Mannitol (100mg/bottle) was used as filler.The quality of YSFP was studied, and the quality specification was built up to agree with the quality requirements of Chinese herbal freeze-drying preparation for injection. The quality could be controlled by the specification established considerably and the clinical safety could be ensured.HPLC-ELSD method for sing saponins, HPLC method for schizandrol A, UV methods for total saponins and total lignans were used to determine their contents in the preparation, which regulated the determination should be more than 21.0, 0.38, 67.0, 1.50mg/bottle.
Fingerprint chromatograms of Ophiopogon japonicus, Schisandra chinensis, the intermediates and the preparation were established to control their qualities. Results of tests for HPLC methods of the fingerprint chromatograms were up to grade. Total area ratio of all the uncommon peaks, relative retention time and relative area ratio of the common peaks all met the related requirements for fingerprint chromatograms of 10 batches of Ophiopogon japonicus, Schisandra chinensis, the intermediates and the preparation.
To assess whether there was a potential risk of hemolysis, stimulus and allergy, experiments were proceed and the result showed that the product was safety. The acute toxicity test of YSFP concluded that the LD_(50) and confidential interval (95%), correspondingly, were 492.9mg/kg and 438.2~554.5 mg/kg.
The result of pharmacodynamics studies showed that there was significant inhibition on changes of electrocardiogram caused by isoprenaline hydrochloride injection after intraperitoneal injection of YSFP to rats(16.8mg/kg); significant prolongation of electrocardio disappear time and decrease on incidence rate of cardiac ventricle jitter caused by chloroform after intravenous injection of YSFP to mice(24mg/kg), significant decrease of maintaining time of arrhythmia caused by barium chloride after intravenous injection of YSFP to mice(16.8mg/kg). All these data indicated its potential application on therapy of ischemic heart disease and arrhythmia.
引文
[1] 部颁标准WS_3-B-2865-98生脉注射液,Z15-50.
[2] 王红燕,林雁.静滴参麦注射液出现不良反应2例[J].中国中药杂志,2002,27(7):558.
[3] 张洪忠,于鹏飞.参麦注射液诱发心绞痛1例[J].临床心血管杂志,1996,12(6):415.
[4] 周小琳,杨运清.大量参麦注射液致严重腹胀4例[J].国医论坛,1996,11(2):36.
[5] 罗康.参麦注射液致过敏性休克1例[J].广西中医药,1996,19(2):39.
[6] 吴继萍,朱丽文.参麦注射液致过敏性休克1例[J].中国医院药学杂志,2000,10(2):75.
[7] 张正康,施国翠.34例人参不良反应分析[J].时珍国医国药 1999,10(4):311
[8] 陈立,杨世杰,陈霞.西洋参皂苷单体pF)l对心血管作用的初步观察[J].白求恩医科大学学报,1995,21(1):20~22.
[9] 孟勤,孙平,赵俊艳.西洋参皂苷溶血作用的观察[J].中国药学杂志,1996,31(12):755~756.
[10] 孟祥颖,任跃英,李向高等.西洋参中皂苷类成分的研究综述[J].特产研究,2001,11(3):43~47.
[11] 孙贵波,徐惠波等.洋参叶二醇组皂苷抗急性心肌缺血作用研究[J].中国新药与临床药理,2002;13(2):82.
[12] 睢大员,于晓风等.西洋参叶20s-原人参二醇组皂苷对犬急性心肌梗死的保护作用[J].中国药学杂志,2001;26(6):416~419.
[13] 刘尚裕,睢大员等.西洋参叶20s-原人参二醇组皂苷对急性心肌梗死犬血流动力学和氧代谢的影响[J].中国药学杂志,2001;36(1):25.
[14] 武淑芳,睢大员等.西洋参叶20s-原人参二醇组皂苷抗实验性心肌缺血作用及机制[J].中国药学杂志,2002;37(2):100
[15] 孟祥颖,任跃英等.西洋参在心血管方面的药理作用[J].人参研究,1998:(2):7.
[16] 李吉平,刘洁等.西洋参茎叶二醇皂苷对低密度脂蛋白氧化修饰的影响[J].中国药理学会通讯,2000;14(4):22.
[17] 刘玉梅,于倩,李淑英等.西洋参二醇组皂苷注射液的研制及临床研究[J].中国药学杂志,1997;32(10):619~621.
[18] 易进海,麦冬研究进展[J].华西药学杂志,1991:8(1):32~38.
[19] 虞天锡.麦冬对心肌缺血时心脏血液动力学影响的临床和实验研究[J].上海中医药杂志,1985(12):3~7.
[20] 韦德慧.麦冬注射液对实验性急性心肌缺血的影响[J].第一军医大学学报,1984,4(1P2):41243.
[21] 张宝恒,齐治,温淑容等.几种中药连续给药与单次给药对小鼠心肌摄取Rb86作用的比较[J].北京医学院学报,1981,4(13):299.
[22] 张宝恒,马丽,骆宝等.几种中草药对小鼠心肌营养血流量的影响[J].中药通报,1985,10(2):42.
[23] 李文萍,方军.麦冬注射液对实验性心肌梗塞时环核苷酸代谢的影响[J].中西医结合杂志,1986,9(2):100.
[24].韦德蕙,杨淑琴,刘菊芳等.麦冬注射液的抗实验性心律失常和对离体心脏的作用[J].中草药,1982:13(9):27.
[25] 顾双林,纪克等.麦冬对实验性心肌梗塞及心肌缺氧时亚微结构的影响[J].上海中医药杂志,1983;(7):44~45.
[26] 田友清,余伯阳等.麦冬药理研究进展[J].中国医学生物技术应用杂志,2004;(2):1.
[27] 韦德蕙,曹维等.麦冬注射液对失血性休克大鼠血压及左心室功能的影响[J].第一军医大学学报,1989;9(1):7~9.
[28] 黄厚才,倪正.麦冬对小鼠小鼠耳廓微循环的响[J].2003,23(1):57~58.
[29] 黄厚才,倪正,蔡雪珠.麦冬对大鼠血小板聚集率的影响[J].上海实验动物科学,2001;21(3):167~168.
[30] 李民,张旭,龚婕宁,卞慧敏,等.麦冬药物血清抗血管内皮细胞调亡的分子机制[J].南京中医药大学学报(自然科学版),2001;17(5):289~290.
[31] 张旭,张超英,王文等.麦冬药物血清对血管内皮细胞调亡相关基因表达及胞内Ca2~+的影响[J].中国病理生理杂志,2003;19(6)789~791.
[32] 周惠芳,张旭,吴德芹.麦冬对诱导性血管平滑肌细胞增殖的拮抗作用[J].浙江中西医结合杂志,2003:13(9):531~533.
[33] 张易水,刘祥忠,李华.麦冬对衰老模型大鼠抗衰老作用的研究[J].深圳中西医结合杂志,1999:9(6):26~27.
[34] 郭晶,陈非,李丽华等.中药麦冬对D-半乳糖衰老模型大鼠血液流变性的影响[[J].中国微循环杂志,2002;6(4):246.
[35] 上海中医学院附属曙光医院内科冠心病防治组.麦冬治疗冠心病的临床疗效及实验观察[J].中华内科杂志.1976.4:210~211.
[36] 虞天锡.麦冬对心肌缺血时心脏血液动力学影响的临床和实验研究[J].上海中医药杂志,1985(12):3~7.
[37] 芮和恺,季伟良.五味子挥发油成分的研究[J].中药材,1991,14(7):38.
[38] 包天桐.五味子的研究Ⅲ五味子乙素的某些药理作用[J].中华医学杂志,1975,55(7):49.
[39] 睢大员,高普军,吕忠志,等.北五味子粗多糖保肝作用的药理研究[J].吉林中医药,1995,23(1):37.
[40] 张林魁,钮心懿.五味子醇甲对中枢神经系统单胺类递质的影响[J].中国医学科学院学报,1991,13(1):13.
[41] 钮心懿.五味子有效成分“醇甲”对中枢神经系统作用[J].药学学报,1983,18(6):416~421.
[42] 陈国千.五味和刺五加对老年大鼠心肌环核苷酸系统的影响[J].中药药理与临床,1992,8(2):36~37.
[43] 彭国瑞,许志奇,曾祥国,等.五味子对家兔泌尿生殖系统酶组织化学的影响及其抗衰老作用的初步观察[J].上海中医药杂志,1989,2:43.
[44] 周忠光.五味子对小鼠大脑皮质内毛细血管超微结构影响的研究-抗衰老试验[J].中医药学报,1992,4:47
[45] 末川守.五味子对动物药理作用的实验观察[J].药学杂志,1987,107(9):720.
[46] 曾祥国,许志奇,彭国瑞,等.五味子对家兔心血管酶组织化的药理作用研究[J].四川中医,1990,8(4):10.
[47] 刘彬果,郭文勇,钟蕾等.大孔树脂吸附技术在中药制剂中的应用[J].解放军药学学报,2003,19(6):452~453.
[48] 程莉,龚耀刚,安凯等.大孔树脂在三七叶皂苷脱色中的应用研究[J].云南中医学院学报,2005,28(3):13~14.
[49] 王彦涵,高建平,陈道峰.高效液相色谱法测定五味子属药用植物木脂素的含量.中国中药杂志,2003,28(12):1156.
[50] 汉城国立大学药学院.高效液相色谱法-蒸发光检测器用于人参皂苷的测定[J].药物分析杂志,1996,16(6):412~414.
[51] 秦少容,余佳文,岳廷哲等.高效液相色谱法-蒸发光散射检测器法测定红参及育精胶囊中人参皂苷Rg_1和Re的含量[J].中国中药杂志,2001,26(8):544~546.
[52] 林辉,张谢稍,郭鸿宜.pH值对西洋参水溶液稳定性影响的考察[J].中成药,1998,20(10):4~6.
[53] 邓凯顺,顾兰智.冷冻干燥工艺的原理及应用[J].河北化工,2004,12(1):24~25.
[54] 曾军.冷冻干燥的设备性能选择以及配方研究、冻干工艺经验[J].海峡药学,2001,13(1):99~100.
[55] 郭玺权,李宁,陈宁.冻干制剂工艺的探索[J].药学进展,1999,23(4):234~237.
[56] 张峻,刘炜.红花注射液与输液配伍的不溶性微粒考察[J].海峡药学,2003,15(2):19~20.
[57] 国家药品监督管理局.中药注射剂指纹图谱研究的技术要求(暂行).2000.
[58] Liang Y. Z., Xie P. S., et. al. Quality control of herbal medicines. [J] Journal of Chromatography B.2004, 812: 53~70.
[59] 国家药品监督管理局.中药、天然药物局部刺激性和溶血性研究技术指导原则(第二稿).2004.
[60] 国家药品监督管理局.中药、天然药物免疫毒性(过敏性、光变态反应)研究技术指导原则(第二稿).2004.